Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia Vera.

ABSTRACT: Within 15 years of diagnosis, around 15% of polycythemia vera (PV) cases progress to post-PV myelofibrosis, and around 3% transform to acute myeloid leukemia within 10 years. Risk factors for disease progression include advanced age and the presence of certain acquired myeloid-relevant mutations. A better understanding of what defines disease progression in PV is essential when evaluating treatment options that enable disease modification and improved patient outcomes. A modified-Delphi method was used to convene a virtual steering group (SG) of seven US-based clinical physicians specializing in the management and treatment of PV. The group generated 41 consensus statements across six main domains. A survey was developed from these statements and shared with a broader panel of specialists,

SUBMITTER: Bose P 

PROVIDER: S-EPMC12619767 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature